| . | Risk group (points) . | # with IM/total in risk group (%) . | Likelihood ratio . |
|---|---|---|---|
| IM-NoLab risk score | |||
| Derivation cohort | Low risk (0–1 points) | 51/677 (7.6%) | 0.40 |
| High risk (2+ points) | 175/664 (27.0%) | 1.77 | |
| Validation cohort | Low risk (0–1 points) | 29/365 (7.9%) | 0.46 |
| High risk (2+ points) | 101/455 (22.2%) | 1.51 | |
| IM-Lab risk score | |||
| Derivation cohort | Low risk (0 points) | 14/954 (1.5%) | 0.07 |
| Moderate risk (1–2.5 points) | 20/118 (16.9%) | 1.02 | |
| High risk (3+ points) | 182/219 (83.1%) | 24.5 | |
| Validation cohort | Low risk (0 points) | 22/611 (3.6%) | 0.19 |
| Moderate risk (1–2.5 points) | 11/88 (12.5%) | 0.71 | |
| High risk (3+ points) | 92/105 (87.6%) | 35.2 | |
| . | Risk group (points) . | # with IM/total in risk group (%) . | Likelihood ratio . |
|---|---|---|---|
| IM-NoLab risk score | |||
| Derivation cohort | Low risk (0–1 points) | 51/677 (7.6%) | 0.40 |
| High risk (2+ points) | 175/664 (27.0%) | 1.77 | |
| Validation cohort | Low risk (0–1 points) | 29/365 (7.9%) | 0.46 |
| High risk (2+ points) | 101/455 (22.2%) | 1.51 | |
| IM-Lab risk score | |||
| Derivation cohort | Low risk (0 points) | 14/954 (1.5%) | 0.07 |
| Moderate risk (1–2.5 points) | 20/118 (16.9%) | 1.02 | |
| High risk (3+ points) | 182/219 (83.1%) | 24.5 | |
| Validation cohort | Low risk (0 points) | 22/611 (3.6%) | 0.19 |
| Moderate risk (1–2.5 points) | 11/88 (12.5%) | 0.71 | |
| High risk (3+ points) | 92/105 (87.6%) | 35.2 | |
| . | Risk group (points) . | # with IM/total in risk group (%) . | Likelihood ratio . |
|---|---|---|---|
| IM-NoLab risk score | |||
| Derivation cohort | Low risk (0–1 points) | 51/677 (7.6%) | 0.40 |
| High risk (2+ points) | 175/664 (27.0%) | 1.77 | |
| Validation cohort | Low risk (0–1 points) | 29/365 (7.9%) | 0.46 |
| High risk (2+ points) | 101/455 (22.2%) | 1.51 | |
| IM-Lab risk score | |||
| Derivation cohort | Low risk (0 points) | 14/954 (1.5%) | 0.07 |
| Moderate risk (1–2.5 points) | 20/118 (16.9%) | 1.02 | |
| High risk (3+ points) | 182/219 (83.1%) | 24.5 | |
| Validation cohort | Low risk (0 points) | 22/611 (3.6%) | 0.19 |
| Moderate risk (1–2.5 points) | 11/88 (12.5%) | 0.71 | |
| High risk (3+ points) | 92/105 (87.6%) | 35.2 | |
| . | Risk group (points) . | # with IM/total in risk group (%) . | Likelihood ratio . |
|---|---|---|---|
| IM-NoLab risk score | |||
| Derivation cohort | Low risk (0–1 points) | 51/677 (7.6%) | 0.40 |
| High risk (2+ points) | 175/664 (27.0%) | 1.77 | |
| Validation cohort | Low risk (0–1 points) | 29/365 (7.9%) | 0.46 |
| High risk (2+ points) | 101/455 (22.2%) | 1.51 | |
| IM-Lab risk score | |||
| Derivation cohort | Low risk (0 points) | 14/954 (1.5%) | 0.07 |
| Moderate risk (1–2.5 points) | 20/118 (16.9%) | 1.02 | |
| High risk (3+ points) | 182/219 (83.1%) | 24.5 | |
| Validation cohort | Low risk (0 points) | 22/611 (3.6%) | 0.19 |
| Moderate risk (1–2.5 points) | 11/88 (12.5%) | 0.71 | |
| High risk (3+ points) | 92/105 (87.6%) | 35.2 | |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
